196 related articles for article (PubMed ID: 28314927)
21. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of PPARĪ³ agonist in acute nephrotic syndrome.
Zuo Y; Yang HC; Potthoff SA; Najafian B; Kon V; Ma LJ; Fogo AB
Nephrol Dial Transplant; 2012 Jan; 27(1):174-81. PubMed ID: 21565943
[TBL] [Abstract][Full Text] [Related]
23. Expression of Cathepsin L and Its Intrinsic Inhibitors in Glomeruli of Rats With Puromycin Aminonucleoside Nephrosis.
Kubo A; Shirato I; Hidaka T; Takagi M; Sasaki Y; Asanuma K; Ishidoh K; Suzuki Y
J Histochem Cytochem; 2018 Dec; 66(12):863-877. PubMed ID: 30052474
[TBL] [Abstract][Full Text] [Related]
24. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin.
Reiser J; Oh J; Shirato I; Asanuma K; Hug A; Mundel TM; Honey K; Ishidoh K; Kominami E; Kreidberg JA; Tomino Y; Mundel P
J Biol Chem; 2004 Aug; 279(33):34827-32. PubMed ID: 15197181
[TBL] [Abstract][Full Text] [Related]
25. Modulation of cytoskeletal organization of podocytes during the course of aminonucleoside nephrosis in rats.
Kubosawa H; Kondo Y
Pathol Int; 1994 Aug; 44(8):578-86. PubMed ID: 7952147
[TBL] [Abstract][Full Text] [Related]
26. Mechanism Underlying Selective Albuminuria in Minimal Change Nephrotic Syndrome.
Tojo A
Int J Nephrol; 2019; 2019():5859102. PubMed ID: 31781392
[TBL] [Abstract][Full Text] [Related]
27. Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes.
Jeruschke S; Alex D; Hoyer PF; Weber S
Sci Rep; 2022 Jul; 12(1):12297. PubMed ID: 35853959
[TBL] [Abstract][Full Text] [Related]
28. Alteration in the podoplanin-ezrin-cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome.
Suzuki K; Fukusumi Y; Yamazaki M; Kaneko H; Tsuruga K; Tanaka H; Ito E; Matsui K; Kawachi H
Cell Tissue Res; 2015 Oct; 362(1):201-13. PubMed ID: 25920588
[TBL] [Abstract][Full Text] [Related]
29. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat.
Kim YH; Goyal M; Kurnit D; Wharram B; Wiggins J; Holzman L; Kershaw D; Wiggins R
Kidney Int; 2001 Sep; 60(3):957-68. PubMed ID: 11532090
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of markers of podocyte injury in the rat puromycin aminonucleoside nephropathy model.
Kakimoto T; Okada K; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
Exp Toxicol Pathol; 2015 Feb; 67(2):171-7. PubMed ID: 25481214
[TBL] [Abstract][Full Text] [Related]
31. Alterations in proteoglycan metabolism in the nephrotic syndrome induced by the aminonucleoside of puromycin.
Klein DJ; Dehnel PJ; Oegema TR; Brown DM
Lab Invest; 1984 May; 50(5):543-51. PubMed ID: 6232422
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of the cytoskeletal-associated protein, paxillin, in experimental nephrotic syndrome.
Koukouritaki SB; Tamizuddin A; Lianos EA
J Investig Med; 1998 Aug; 46(6):284-9. PubMed ID: 9737090
[TBL] [Abstract][Full Text] [Related]
33. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins.
Wada T; Pippin JW; Marshall CB; Griffin SV; Shankland SJ
J Am Soc Nephrol; 2005 Sep; 16(9):2615-25. PubMed ID: 15987750
[TBL] [Abstract][Full Text] [Related]
34. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
Aizawa K; Takeda S; Tashiro Y; Yorozu K; Hirata M; Kanada H; Moriguchi Y; Endo K
Am J Nephrol; 2012; 36(5):419-26. PubMed ID: 23128049
[TBL] [Abstract][Full Text] [Related]
35. The struggle for energy in podocytes leads to nephrotic syndrome.
Yan K; Ito N; Nakajo A; Kurayama R; Fukuhara D; Nishibori Y; Kudo A; Akimoto Y; Takenaka H
Cell Cycle; 2012 Apr; 11(8):1504-11. PubMed ID: 22433955
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode.
Kawakami H; Kamiie J; Yasuno K; Kobayashi R; Aihara N; Shirota K
Nephrol Dial Transplant; 2012 Apr; 27(4):1324-30. PubMed ID: 21862459
[TBL] [Abstract][Full Text] [Related]
37. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Xiao H; Shi W; Liu S; Wang W; Zhang B; Zhang Y; Xu L; Liang X; Liang Y
Am J Nephrol; 2009; 30(1):34-43. PubMed ID: 19202327
[TBL] [Abstract][Full Text] [Related]
38. Protective effects of tadalafil on damaged podocytes in an adriamycin-induced nephrotic syndrome model.
Tomita N; Hotta Y; Naiki-Ito A; Sanagawa A; Kataoka T; Furukawa-Hibi Y; Takahashi S; Kimura K
J Pharmacol Sci; 2022 Jun; 149(2):53-59. PubMed ID: 35512855
[TBL] [Abstract][Full Text] [Related]
39. Over-expression of adenosine deaminase in mouse podocytes does not reverse puromycin aminonucleoside resistance.
Brideau G; Doucet A
BMC Nephrol; 2010 Jul; 11():15. PubMed ID: 20649959
[TBL] [Abstract][Full Text] [Related]
40. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
